About: SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.23 (+0.94%)
SABS NASDAQ SAB Biotherapeutics Inc
SAB Biotherapeutics Inc share price
Atividade de preço de SABS
Último preço
$ 3,230
Variação (24h)
0,03 USD (0,94%)
Volume
458.27K
Volume (média 4 sem.)
-
Abertura
$ 3,16
Variação do dia
$ 3,16 - $ 3,36
Fechamento anterior
$ 3,20
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
SABS price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals